Table 1

Clinical features of the included patients and controls

Patients
(n=36)
Healthy controls
(n=36)
SCD controls
(n=21)
Gender, n (%)
 Female24 (67%)24 (67%)10 (48%)
Geographic origin, n (%)
 Sub-Saharan Africa/West Indies23 (64%)0 (0%)21 (100%)
 North Africa6 (17%)0 (0%)0 (0%)
 Europe5 (14%)36 (100%)0 (0%)
 Asia/Middle East2 (5%)0 (0%)0 (0%)
Age at diagnosis (years), median, (IQR)**12.4 (9.53–13.15)
Age at inclusion (years), median, (IQR)††19.7 (15–23)19.8 (5–38)16.7 (3–30)
Number of coresidents, median (IQR)3 (2.75–3)3 (3–3)2.7 (2–3)
Family cases, n (%)3 (8.3%)
Clinical features at diagnosis, n (%)
 General fatigue17 (47%)
 Fever13 (36%)
 Weight loss7 (47%)
 Pulmonary localisation34 (94%)
 Extrapulmonary localisation34 (94%)
  Liver21 (58%)
  Lymphadenopathies17 (47%)
  Salivary glands14 (39%)
  Eyes13 (36%)
  Spleen7 (19.4%)
  Joints7 (19.4%)
  Skin5 (14%)
  Stomach5 (14%)
  Kidney4 (11%)
  Bone marrow2 (5.5%)
  Heart2 (5.5%)
  Tonsils1 (2.7%)
Histology, n (%)
 Non-caseating granuloma33 (91.7%)
Treatments, n (%)
 Corticosteroids, n (%)34 (94%)
  Oral only12 (33%)
  Intravenous pulse only1 (2.9%)
  Both oral and intravenous21 (58%)
 Other drugs‡10 (27.7%)
 No treatment2 (5.5%)
  • The explorations assessing the sarcoidosis diagnosis of the 36 included patients are provided in online supplemental table S1.

  • IQR: 25–75.

  • *Extreme values (minimal–maximal) (1–15.9).

  • †Extreme values (minimal–maximal) (4–36), (5–38) and (3–30), respectively.

  • ‡Methotrexate, azathioprine, hydroxychloroquine, mycophenolate mofetil.

  • SCD, sickle-cell disease.